All Outputs (234)

Tumour heterogeneity of breast cancer: from morphology to personalised medicine (2018)
Journal Article
Aleskandarany, M. A., Vandenberghe, M. E., Marchiò, C., Ellis, I. O., Sapino, A., & Rakha, E. A. (2018). Tumour heterogeneity of breast cancer: from morphology to personalised medicine. Pathobiology, 85(1-2), 23-34. https://doi.org/10.1159/000477851

Breast cancer (BC) displays striking clinical, morphological, and behavioural diversity within a single tumour and between tumours. Currently, mounting evidence indicates that the morphological heterogeneity of BC reflects an underlying spectrum of g... Read More about Tumour heterogeneity of breast cancer: from morphology to personalised medicine.

Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis (2018)
Journal Article
Kurozumi, S., Joseph, C., Sonbul, S., Gorringe, K. L., Pigera, M., Aleskandarany, M. A., …Rakha, E. A. (in press). Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. Breast Cancer Research and Treatment, 170(3), https://doi.org/10.1007/s10549-018-4777-z

Background: The functions of many proteins are tightly regulated with a complex array of cellular functions including ubiquitination. In cancer cells, aberrant ubiquitination may promote the activity of oncogenic pathways with subsequent tumour progr... Read More about Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.

Diagnostic concordance of reporting lymphovascular invasion in breast cancer (2018)
Journal Article
Rakha, E. A., Abbas, A., Pinto Ahumada, P., ElSayed, M. E., Colman, D., Pinder, S. E., & Ellis, I. O. (2018). Diagnostic concordance of reporting lymphovascular invasion in breast cancer. Journal of Clinical Pathology, 71(9), (802-805). doi:10.1136/jclinpath-2017-204981. ISSN 0021-9746

Aims: This study aims to assess the diagnostic agreement of lymphovascular invasion (LVI) in invasive breast cancer (BC). Methods: Data on LVI were collected from the UK National Health Service Breast Screening Programme pathology external quality... Read More about Diagnostic concordance of reporting lymphovascular invasion in breast cancer.

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes (2018)
Journal Article
Joseph, C., Macnamara, O., Craze, M., Russell, R., Provenzano, E., Nolan, C. C., …Mukherjee, A. (in press). Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. British Journal of Cancer, https://doi.org/10.1038/s41416-018-0041-x

Background: Mediator complex (MED) proteins have a key role in transcriptional regulation, some interacting with the oestrogen receptor (ER). Interrogation of the METABRIC cohort suggested that MED7 may regulate lymphovascular invasion (LVI). Thus ME... Read More about Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours (2018)
Journal Article
El Ansari, R., Craze, M. L., Miligy, I., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., …Green, A. R. (in press). The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Research, 20(21), https://doi.org/10.1186/s13058-018-0946-6

Background: Breast cancer (BC) is a heterogeneous disease characterised by variant biology and patient outcome. The amino acid transporter, SLC7A5, plays a role in BC although its impact on patient outcome in different BC subtypes remains to be valid... Read More about The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.

Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast (2018)
Journal Article
Toss, M. S., Miligy, I., Al-Kawaz, A., Alsleem, M., Khout, H., Rida, P. C., …Rakha, E. (in press). Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Modern Pathology, https://doi.org/10.1038/s41379-018-0040-8

Tumor-infiltrating lymphocytes (TILs) provide prognostic value in invasive breast cancer and guidelines for their assessment have been published. This study aims to evaluate: (a) methods of TILs assessment, and (b) their prognostic significance in br... Read More about Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes (2018)
Journal Article
El Ansari, R., Craze, M. L., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2018). The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. British Journal of Cancer, 118(8), 1115-1122. https://doi.org/10.1038/s41416-018-0038-5

Background: Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity and patient outcome. This study aimed to evaluate the biological and prognostic value of the membrane solute carrier, SLC3A2 in BC with emp... Read More about The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.

Breast cancer histologic grading using digital microscopy: concordance and outcome association (2018)
Journal Article
Rakha, E. A., Aleskandarani, M., Toss, M. S., Green, A. R., Ball, G., Ellis, I. O., & Dalton, L. W. (2018). Breast cancer histologic grading using digital microscopy: concordance and outcome association. Journal of Clinical Pathology, 71(8), 680-686. doi:10.1136/jclinpath-2017-204979

AIMS: Virtual microscopy utilising digital whole slide imaging (WSI) is increasingly used in breast pathology. Histologic grade is one of the strongest prognostic factors in breast cancer (BC). This study aims at investigating the agreement between B... Read More about Breast cancer histologic grading using digital microscopy: concordance and outcome association.

Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort (2018)
Journal Article
Mukherjee, A., Russell, R., Chin, S., Liu, B., Rueda, O., Ali, H., …Provenzano, E. (2018). Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. npj Breast Cancer, 4(1), Article 5. https://doi.org/10.1038/s41523-018-0056-8

The integration of genomic and transcriptomic profiles of 2000 breast tumours from the METABRIC [Molecular Taxonomy of Breast Cancer International Consortium] cohort revealed ten subtypes, termed integrative clusters (IntClust/s), characterised by di... Read More about Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

Immune infiltration in invasive lobular breast cancer (2018)
Journal Article
Desmedt, C., Salgado, R., Fornili, M., Pruneri, G., Gert Van den Eynden, G., Zoppoli, G., …Sotiriou, C. (2018). Immune infiltration in invasive lobular breast cancer. JNCI: Journal of the National Cancer Institute, 110(7), 768–776. https://doi.org/10.1093/jnci/djx268

Background: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels and composition of tumor infiltrating lymphocytes... Read More about Immune infiltration in invasive lobular breast cancer.

First international TNBC conference meeting report (2018)
Journal Article
Rida, P., Ogden, A., Ellis, I. O., Varga, Z., Wolff, A. C., Traina, T. A., …Aneja, R. (2018). First international TNBC conference meeting report. Breast Cancer Research and Treatment, 169(3), 407-412. https://doi.org/10.1007/s10549-018-4692-3

Recently, Georgia State University’s Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from Sept. 18 to 20, 2017, in Atlanta, USA. T... Read More about First international TNBC conference meeting report.

Targeting ataxia telangiectasia mutated and Rad3 related kinase (ATR) in PTEN deficient breast cancers for personalized therapy (2018)
Journal Article
Al-Subhi, N., Ali, R., Abdel-Fatah, T., Moseley, P. M., Chan, S. Y., Green, A. R., …Madhusudan, S. (2018). Targeting ataxia telangiectasia mutated and Rad3 related kinase (ATR) in PTEN deficient breast cancers for personalized therapy. Breast Cancer Research and Treatment, 169(2), 277–286. https://doi.org/10.1007/s10549-018-4683-4

Purpose: PTEN, a negative regulator of PI3K signaling, is involved in DNA repair. ATR is a key sensor of DNA damage and replication stress. We evaluated whether ATR signaling has clinical significance and could be targeted by synthetic lethality in P... Read More about Targeting ataxia telangiectasia mutated and Rad3 related kinase (ATR) in PTEN deficient breast cancers for personalized therapy.

BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer (2018)
Journal Article
Gong, C., Man, E. P., Tsoi, H., Lee, T. K., Paul, L., Mak, S., …Khoo, U. (2018). BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer. Clinical Cancer Research, 24(15), 3681-3691. https://doi.org/10.1158/1078-0432.CCR-17-2259

Purpose: Adjuvant tamoxifen treatment revolutionized the management of estrogen receptor (ER) positive breast cancers to prevent cancer recurrence; however drug resistance compromises its clinical efficacy. The mechanisms underlying tamoxifen resista... Read More about BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer.

High nuclear MSK1 is associated with longer survival in breast cancer patients (2018)
Journal Article
Pu, X., Storr, S. J., Ahmad, N., Rakha, E., Green, A. R., Ellis, I. O., & Martin, S. G. (2018). High nuclear MSK1 is associated with longer survival in breast cancer patients. Journal of Cancer Research and Clinical Oncology, 144(3), https://doi.org/10.1007/s00432-018-2579-7

Purpose: Mitogen- and stress- activated kinases (MSKs) are important substrates of the mitogen-activated protein kinase (MAPK)-activated protein kinase family. MSK1 and MSK2 are both nuclear serine/threonine protein kinases, with MSK1 being suggested... Read More about High nuclear MSK1 is associated with longer survival in breast cancer patients.

IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients (2017)
Journal Article
Ahmad, N., Ammar, A., Storr, S. J., Green, A. R., Rakha, E., Ellis, I., & Martin, S. G. (2018). IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunology, Immunotherapy, 67(4), https://doi.org/10.1007/s00262-017-2106-8

Macrophage-associated cytokines play an important role in cancer metastasis however the functions of Interleukins (IL) 6 and 10 in breast cancer (BC) progression and metastasis are not clear. In this study the roles of IL-6/IL-10 in regulating vascul... Read More about IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients.

Invasion in breast lesions: the role of the epithelial-stroma barrier (2017)
Journal Article
Rakha, E. A., Miligy, I., Gorringe, K. L., Toss, M. S., Green, A. R., Fox, S. B., …Ellis, I. O. (2018). Invasion in breast lesions: the role of the epithelial-stroma barrier. Histopathology, 72(7), 1075-1083. https://doi.org/10.1111/his.13446

Despite the significant biological, behavioural and management differences between ductal carcinoma in situ (DCIS) and invasive carcinoma of the breast, they share many morphological and molecular similarities. Differentiation of these two different... Read More about Invasion in breast lesions: the role of the epithelial-stroma barrier.

Diagnostic challenges in papillary lesions of the breast (2017)
Journal Article
Rakha, E. A., & Ellis, I. O. (2017). Diagnostic challenges in papillary lesions of the breast. Pathology, 50(1), (100-110). doi:10.1016/j.pathol.2017.10.005. ISSN 0031-3025

Papillary lesions of the breast comprise a heterogeneous group of diseases ranging from benign and atypical lesions to malignant tumours including non-invasive and invasive entities. Although diagnosis of papillary lesions featuring typical histologi... Read More about Diagnostic challenges in papillary lesions of the breast.

MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer (2017)
Journal Article
Craze, M. L., Cheung, H., Jewa, N., Coimbra, N. D., Soria, D., El-Ansari, R., …Green, A. R. (in press). MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer. British Journal of Cancer, https://doi.org/10.1038/bjc.2017.387

Background: Altered cellular metabolism is a hallmark of cancer and some are reliant on Glutamine for sustained proliferation and survival. We hypothesise that the Glutamine-Proline regulatory axis has a key role in Breast cancer (BC) in the highly p... Read More about MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer.

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2 (2017)
Journal Article
Abdel-Fatah, T. M., Rees, R. C., Pockley, A. G., Moseley, P., Ball, G. R., Chan, S. Y., …Miles, A. K. (2017). The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2. Oncotarget, 8(68), 112245-112257. https://doi.org/10.18632/oncotarget.22496

Cancer biomarkers that can define disease status and provide a prognostic insight are essential for the effective management of patients with breast cancer (BC). The prevalence, clinicopathological and prognostic significance of PRPF38B expression... Read More about The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.

Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer (2017)
Journal Article
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F., Haider, S., Kriplani, D., …Natrajan, R. (2018). Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer. Molecular Cancer Therapeutics, 17(1), 306-315. https://doi.org/10.1158/1535-7163.mct-17-0760

Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. We therefore aimed to assess t... Read More about Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer.